Key result
A single dose of Havrix resulted in a higher overall seroconversion rate compared to Epaxal at 11 months, driven primarily by lower immunogenicity of Epaxal in men.
Why the study?
Does a single dose of Havrix compared to Epaxal improve seroconversion rates in young adults?
RCT (n=451)
randomly allocated
Yes
Does a single dose of Havrix compared to Epaxal improve seroconversion rates in young adults?
A single dose of HAV vaccine resulted in a lower seroconversion rate in men, particularly with Epaxal, suggesting gender effects should be considered in vaccine immunogenicity.
Answers are grounded in this paper and cite their sources.
Supports preferring Havrix over Epaxal for single-dose HAV vaccination in young men; extends evidence for sex-specific immunogenicity differences.
PURPOSE: Assessing the immunogenicity of a single dose of hepatitis A virus (HAV) vaccines is important because some people receive only a single dose. However, previous studies have shown variable results and have not examined the effects of demographic characteristics other than gender. This study was performed to examine the immunogenicity of a single dose of HAV vaccine according to the vaccine type and demographic characteristics in young adults. MATERIALS AND METHODS: Seronegative medical school students were randomly allocated to receive either Havrix or Epaxal. RESULTS: After approximately 11 months, the seroconversion rate in 451 participants was 80.7%. In men, the Havrix group showed a significantly higher seroconversion rate (81.9%) than the Epaxal group (69.2%), whereas both vaccine groups showed similarly high immunogenicity in women (Havrix: 90.1%, Epaxal: 92.9%; P for interaction=0.062). According to the results of a multivariate analysis, Epaxal showed significantly lower immunogenicity than Havrix only in men. Age, obesity, drinking, smoking, and follow-up time did not significantly affect seroconversion in either gender. CONCLUSION: The seroconversion rate of single-dose HAV vaccines was low in men, particularly in those who received Epaxal. Our results suggest that gender effects should be considered when comparing the immunogenicity of different HAV vaccines.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2013) conducted an RCT in Hepatitis A Virus (HAV) seronegative (n=451). Havrix vs. Epaxal was evaluated on Seroconversion rate (anti-HAV antibody titer ≥20 IU/mL) at approximately 11 months (p=0.026). A single dose of Havrix resulted in a higher overall seroconversion rate compared to Epaxal at 11 months, driven primarily by lower immunogenicity of Epaxal in men.
Synapse has enriched 10 related papers. Consider them for comparative context: